title: Small-bowel perforation in very low birth weight neonates treated with high-dose dexamethasone.
abstract: BACKGROUND
  Early postnatal treatment with high doses of corticosteroids may be effective in reducing the duration of mechanical ventilation in very low birth weight infants at risk for bronchopulmonary dysplasia. However, serious side effects may occur.
  
  
  METHODS
  A retrospective study on 5 very low birth weight neonates, mean (+/- SEM): gestational age range 27.5 +/- 2 weeks, mean birth weight (+/- SEM): 836 g +/- 169 referred between April 1997 and October 1998 from a single academic neonatal intensive care unit to our tertiary pediatric surgical center with the diagnosis of intestinal perforation. During the same period, 60 very low birth weight infants have been treated in that unit following a standardized protocol including surfactant for respiratory distress syndrome and high-dose dexamethasone to prevent bronchopulmonary dysplasia.
  
  
  RESULTS
  Pneumoperitoneum was diagnosed between 6 to 9 days after birth. Clinically, all babies remained surprisingly stable. An isolated ileal perforation, without sign of necrotizing enterocolitis, was found at laparotomy in each patient. A limited intestinal resection was performed, with primary end-toend anastomosis (3 cases) or with transient ileostomies (2 cases). Surgical outcome was favorable in all patients.
  
  
  CONCLUSIONS
  isolated intestinal perforation may be a complication of the preventive treatment of chronic lung disease with high-dose corticosteroids in very low birth weight infants. Conversely, corticosteroids may reduce the clinical signs and the multiple organ dysfunction associated with an abdominal drama, explaining the very good surgical prognosis of these newborns. Attention must be paid to an insidious pneumoperitoneum.
authors.affiliation: Department of Pediatric Surgery, University Children Hospital Queen Fabiola, Université Libre de Bruxelles, Belgium. mhdelaet@ulb.ac.be
authors.forename: M H
authors.initials: MH
authors.lastname: De Laet
authors.forename: M
authors.initials: M
authors.lastname: Dassonville
authors.forename: A
authors.initials: A
authors.lastname: Johansson
authors.forename: C
authors.initials: C
authors.lastname: Lerminiaux
authors.forename: V
authors.initials: V
authors.lastname: Seghers
authors.forename: S
authors.initials: S
authors.lastname: Van den Eijnden
authors.forename: D
authors.initials: D
authors.lastname: Blum
authors.forename: J M
authors.initials: JM
authors.lastname: Vanderwinden
mesh_terms: D001997:Bronchopulmonary Dysplasia / Q000517:prevention & control*; D003907:Dexamethasone / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007077:Ileal Diseases / Q000139:chemically induced* / Q000601:surgery; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000601:surgery; D008297:Male; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D003907:Dexamethasone